中文 | English
Return
Total: 111 , 1/12
Show Home Prev Next End page: GO
MeSH:(Phosphodiesterase Inhibitors/*therapeutic use)

1.Update of PDE5 inhibitors for the treatment of ischemia-reperfusion.

Yang-Yang HU ; Zhi-Gang WU

National Journal of Andrology 2011;17(9):842-846

2.Tadalafil for erectile dysfunction: efficacy evaluation.

Xiang WANG

National Journal of Andrology 2009;15(4):379-383

3.Efficacy and safety of vardenafil in difficult-to-treat erectile dysfunction men.

Chuan-hang WANG

National Journal of Andrology 2006;12(4):377-380

4.Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.

De-Feng LIU ; Hui JIANG ; Kai HONG ; Lian-Ming ZHAO ; Wen-Hao TANG ; Lu-Lin MA

Chinese Medical Journal 2010;123(22):3258-3261

5.Advances in the studies of refractory erectile dysfunction.

Bo-Yi WANG ; Rui JIANG

National Journal of Andrology 2013;19(1):82-85

6.Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update.

Rui JIANG

National Journal of Andrology 2013;19(3):195-198

7.Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis.

Qing LIU ; Jian CAI ; Li-zhang LIN ; Cheng-di LI ; Zhi-gang WU

National Journal of Andrology 2015;21(5):447-457

8.Efficacy and safety of tadalafil for erectile dysfunction: an updated review.

Wen-bin RUI ; Xiao-wen CHEN

National Journal of Andrology 2009;15(10):956-959

9.Tadalafil for erectile dysfunction associated with cardiovascular diseases.

Kai-Feng LIU

National Journal of Andrology 2013;19(9):860-863

10.Tadalafil and patients preference in the treatment of erectile dysfunction.

Jian-lin HU ; Bin CHEN

National Journal of Andrology 2006;12(12):1145-1148

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 111 , 1/12 Show Home Prev Next End page: GO